Article

Glycated hemoglobin (HbA1c): old dogmas, a new perspective?

UO di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Clinical Chemistry and Laboratory Medicine (Impact Factor: 2.96). 05/2010; 48(5):609-14. DOI: 10.1515/CCLM.2010.144
Source: PubMed

ABSTRACT The hemoglobin A1c (HbA1c) assay provides a reliable measure of chronic glycemia and correlates well with the risk of long-term diabetes complications, so that it is currently considered the test of choice for monitoring and chronic management of diabetes. Recently, HbA1c testing has been included within the diagnostic criteria recommended for diagnosis of diabetes in nonpregnant individuals by the American Diabetes Association (ADA). The emerging concept that HbA1c can be used rather than blood glucose in the diagnosis of diabetes is highly appealing for a variety of reasons, including less sensitivity to preanalytical variables, lower within subject biological variability, little to null interference from diurnal variations, acute stress and common drugs which are known to influence glucose metabolism, as well as the fact that one single measurement might provide information for both diagnosing diabetes and tracking glycemic control. On the other hand, the use of HbA1c for screening and diagnosing diabetes also carries some limitations, including the worse diagnostic performance in different populations (i.e., pregnancy, elderly and non-Hispanic blacks), the risk of overdiagnosis in subjects with iron deficiency anemia, in subjects genetically predisposed to hyperglycation, and in those with increased red blood cell turnover. There is also a higher risk of misdiagnosis in patients with end-stage renal disease and heavy alcohol consumption. Finally, HbA1c testing might be biased due to the interference from several hemoglobin variants, is characterized by a higher imprecision than blood glucose measurement, and is more expensive. This paper will critically summarize the potential advantages and limitations of HbA1c as a recommended test for diagnosing diabetes.

Download full-text

Full-text

Available from: Giuseppe Lippi, Nov 06, 2014
0 Followers
 · 
165 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Riassunto Nel 2010 l'American Diabetes Association ha inseri-to tra i criteri diagnostici per diabete l'emoglobina glicata. Tale dosaggio sembra avere innegabili van-taggi rispetto alla determinazione della glicemia (mi-nor sensibilità alle variabili pre-analitiche, minor va-riabilità biologica intraindividuale) ma sono ben note condizioni che ne possono inficiare il valore (pazien-ti anziani, presenza di varianti emoglobiniche, side-ropenia, ecc.). Il suo impiego in questo ambito è quin-di oggetto di discussione. Anche lo screening per il diabete mellito gestaziona-le è stato recentemente modificato: la procedura a 2 step con minicarico e successiva curva con sommini-strazione di 100 grammi di glucosio per os nei pa-zienti con minicarico alterato va sostituita da una procedura a step unico con somministrazione di 75 gr di glucosio e prelievi basale, dopo 1ora e dopo 2ore e cut off diagnostici specifici. Summary The laboratory in diabetes: update In a recent report, an international expert committee re-commended the use of HbA1c test to diagnose diabetes and the American Diabetes Association approved the de-cision. HbA1c has several advantages to fasting plasma glucose, such as greater preanalytical stability, less day-to-day perturbation during periods of stress and illness. Ne-vertheless, this test has limitations: the presence of hemo-globin variants or any condition that may change red cell turnover will lead to spurious results. Another important change on diabetes management is re-lated to the screening of gestational diabetes. The recent Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, a large multicenter multinational blinded trial, de-scribed a strong continuos association between maternal glucose concentration and increasing birth weight and markers of perinatal complications. The HAPO study used a 2-hour 75 g glucose load with no preliminary screening based on either risk factors or a challenge test. These resul-ts have led to careful reconsideration of the diagnostic criteria for gestational diabetes mellitus (GDM).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The successful operation of the NCSX machine will require producing plasma configurations with good flux surfaces, with a minimum volume of the plasma lost to magnetic islands or stochastic regions. The project goal is to achieve good flux surfaces over 90% of the plasma volume. NCSX is a three period device designed to be operated with iota ranging from ∼0.4 on axis to ∼0.7 at the edge. The field errors of most concern are those that are resonant with 3/5 and 3/6 modes (for symmetry preserving field errors) and the 1/2 and 2/3 modes (for symmetry breaking field errors). In addition to losses inherent in the physics configuration itself, there will be losses from field errors arising from coil construction and assembly errors. Some of these losses can be recovered through the use of trim coils or correction coils. The impact of coil tolerances on plasma surface quality is evaluated herein for the NCSX design. The methods used in this evaluation are discussed. The ability of the NCSX trim coils to correct for field errors is also examined. The results are used to set coils tolerances for the various coil systems.
    Fusion Engineering, 2003. 20th IEEE/NPSS Symposium on; 11/2003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of diabetes in pregnancy has potentially far-reaching benefits for both pregnant women with diabetes and their children and may provide a cost-effective approach to the prevention of obesity, type 2 diabetes mellitus, and metabolic syndrome. Early and accurate diagnosis of diabetes in pregnancy is necessary for optimizing maternal and fetal outcomes. Optimal control of diabetes in pregnancy requires achieving normoglycemia at all stages of a woman's pregnancy, including preconception and the postpartum period. In this review we focus on new universal guidelines for the screening and diagnosis of diabetes in pregnancy, including the 75-g oral glucose tolerance test, as well as the controversy surrounding the guidelines. We review the best diagnostic and treatment strategies for the pregestational and intrapartum periods, labor and delivery, and the postpartum period, and discuss management algorithms as well as the safety and efficacy of diabetic medications for use in pregnancy. Global guidelines for screening, diagnosis, and classification have been established, and offer the potential to stop the cycle of diabetes and obesity caused by hyperglycemia in pregnancy. Normoglycemia is the goal in all aspects of pregnancy and offers the benefits of decreased short-term and long-term complications of diabetes.
    Clinical Chemistry 02/2011; 57(2):221-30. DOI:10.1373/clinchem.2010.155382 · 7.77 Impact Factor